Treatment of Multiple Myeloma: Best Practices from Yale Cancer Center and Satellites
A Satellite Sessions program at the Yale Cancer Center discusses treatment paradigms and unmet needs in multiple myeloma as well as transplantation, bispecific T-cell engaging therapies, and the importance of collaborative decision-making in clinical practice.
EP. 2: Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Natalia Neparidze, MD, reviews the available induction treatment options for patients with newly diagnosed multiple myeloma (NDMM).
EP. 3: Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD David Witt, MD, details the design and outcomes of the GRIFFIN study in newly diagnosed multiple myeloma.
EP. 4: Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Noffar Bar, MD, explains the GMMG-CONCEPT trial in patients with transplant-eligible NDMM.
EP. 5: Assessing and Treating Patients with High-Risk NDMM
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Elan Gorshein, DO, JD, MPH, describes potential approaches to managing high-risk patients with transplant-eligible NDMM.
EP. 6: Treatment Approaches in Patients With Transplant-Ineligible NDMM
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.
EP. 7: Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.
EP. 8: Available Treatment Options for Patients With R/R MM
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.
EP. 9: Updated Results of the MonumenTAL-1 Study in R/R MM
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.
EP. 10: Application of Bispecific Therapy in Clinical Practice
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.
EP. 11: Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.
EP. 12: Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.
EP. 13: Unmet Needs in the Treatment of Multiple Myeloma
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.
EP. 14: Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites
ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD A Q&A session with the expert panel.
